%0 Journal Article
%T Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis
%A Yi-Ying Wu
%A Anthony J Janckila
%A Chih-Hung Ku
%A Cheng-Ping Yu
%A Jyh-Cherng Yu
%A Su-Hui Lee
%A Hsin-Yi Liu
%A Lung T Yam
%A Tsu-Yi Chao
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-158
%X We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p < 0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.Breast cancer (BC) is the most common malignancy in women. Once metastasis occurs, most patients become incurable. However, metastatic BC is a heterogeneous disease in which some women survive only a few weeks whereas others survive many years. Hormonal receptor status including estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) have been shown to predict treatment response and survival [1]. Patients with metastasis only to bone survive longer than those with visceral metastasis [2]. Nevertheless, patients with bone metastasis still carry heterogeneous outcomes, and the survival time might become shorter when skeletal-related events (SRE) such as pathological fractures, radiation to bones, spinal cord compression, hype
%U http://www.biomedcentral.com/1471-2407/10/158